CSF1R and neoplasm: Strategies that deplete or repolarize TAMs—for instance, by inhibiting the CSF1R pathway—could dismantle the immunosuppressive shield and synergize with ICIs to unleash a more effective anti-tumor T-cell response (Zhu et al., 2019).